Insulin-like growth factors, insulin-like growth factor-binding proteins, insulin-like growth factor-binding protein-3 protease, and growth hormone-binding protein in lipodystrophic Human Immunodeficiency Virus-infected patients

Metabolism: Clinical and Experimental

Volumn 53, Issue 12, 2004, Pages 1565-1573

  Haugaard, Steen B ^a,b   Andersen, Ove ^a,b   Hansen, Birgitte R ^a,b   Ørskov, Hans ^c   Andersen, Ulrik B ^a   Madsbad, Sten ^a   Iversen, Johan ^a   Flyvbjerg, Allan ^c  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GROWTH HORMONE; GROWTH HORMONE BINDING PROTEIN; INDINAVIR; INSULIN; LAMIVUDINE; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3 PROTEASE; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ABDOMEN; ADULT; ARTICLE; BLOOD SAMPLING; BODY FAT; BODY WEIGHT; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN SENSITIVITY; MALE; PRIORITY JOURNAL;

AGE FACTORS; BLOOD GLUCOSE; BODY COMPOSITION; BODY CONSTITUTION; BODY MASS INDEX; C-PEPTIDE; CARRIER PROTEINS; ENDOPEPTIDASES; HIV INFECTIONS; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; LINEAR MODELS; LIPODYSTROPHY; MALE; MIDDLE AGED; SOMATOMEDINS;

EID: 9344265769     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2004.06.025     Document Type: Article

References (49)

1. Carr A., Emery S., Law M., et al. An objective case definition of lipodystrophy in HIV-infected adults A case-control study. Lancet. 361:2003;726-735
2. Koutkia P., Meininger G., Canavan B., et al. Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Am J Physiol. 286:2004;E296-E303
3. Rietschel P., Hadigan C., Corcoran C., et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab. 86:2001;504-510
4. Laursen T., Jorgensen J.O., Christiansen J.S. Metabolic effects of growth hormone administered subcutaneously once or twice daily to growth hormone deficient adults. Clin Endocrinol (Oxf). 41:1994;337-343
5. Marzullo P., Di Somma C., Pratt K.L., et al. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. J Clin Endocrinol Metab. 86:2001;3001-3008
6. Skjaerbaek C., Vahl N., Frystyk J., et al. Serum free insulin-like growth factor-I in growth hormone-deficient adults before and after growth hormone replacement. Eur J Endocrinol. 137:1997;132-137
7. Frystyk J., Vestbo E., Skjaerbaek C., et al. Free insulin-like growth factors in human obesity. Metabolism. 44:1995;37-44
8. Frystyk J., Skjaerbaek C., Vestbo E., et al. Circulating levels of free insulin-like growth factors in obese subjects The impact of type 2 diabetes. Diabetes Metab Rev. 15:1999;314-322
9. Amit T., Youdim M.B., Hochberg Z. Clinical review 112 Does serum growth hormone (GH) binding protein reflect human GH receptor function? J Clin Endocrinol Metab. 85:2000;927-932
10. Baxter R.C. Insulin-like growth factor binding proteins in the human circulation A review. Horm Res. 42:1994;140-144
11. Frystyk J., Skjaerbaek C., Dinesen B., et al. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett. 348:1994;185-191
12. Skjaerbaek C., Frystyk J., Orskov H., et al. Differential changes in free and total insulin-like growth factor I after major, elective abdominal surgery The possible role of insulin-like growth factor-binding protein-3 proteolysis. J Clin Endocrinol Metab. 83:1998;2445-2449
13. Bang P., Brismar K., Rosenfeld R.G. Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130- to 150-kDa ternary complex. J Clin Endocrinol Metab. 78:1994;1119-1127
14. Lassarre C., Lalou C., Perin L., et al. Protease-induced alteration of insulin-like growth factor binding protein-3 as detected by radioimmunoassay Agreement with ligand blotting data. Growth Regul. 4:1994;48-55
15. Puavilai G., Chanprasertyotin S., Sriphrapradaeng A. World Health Organization. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. Diabetes Res Clin Pract. 44:1999;21-26
16. World Health Organization. Diabetes Mellitus Report of a WHO Study Group. 1985;. Geneva World Health Org, Tech Rep Ser, no.727
17. Frystyk J., Dinesen B., Orskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regul. 5:1995;169-176
18. Hossenlopp P., Seurin D., Segovia-Quinson B., et al. Analysis of serum insulin-like growth factor binding proteins using western blotting Use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem. 154:1986;138-143
19. Flyvbjerg A., Kessler U., Dorka B., et al. Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats. Diabetologia. 35:1992;589-593
20. Lamson G., Giudice L.C., Rosenfeld R.G. A simple assay for proteolysis of IGFBP-3. J Clin Endocrinol Metab. 72:1991;1391-1393
21. Fisker S., Frystyk J., Skriver L., et al. A simple, rapid immunometric assay for determination of functional and growth hormone-occupied growth hormone-binding protein in human serum. Eur J Clin Invest. 26:1996;779-785
22. Matsuda M., DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing Comparison with the euglycemic insulin clamp. Diabetes Care. 22:1999;1462-1470
23. Monzavi R., Cohen P. IGFs and IGFBPs Role in health and disease. Best Pract Res Clin Endocrinol Metab. 16:2002;433-447
24. Collett-Solberg P.F., Cohen P. Genetics, chemistry, and function of the IGF/IGFBP system. Endocrine. 12:2000;121-136
25. Hochberg Z., Hertz P., Colin V., et al. The distal axis of growth hormone (GH) in nutritional disorders GH-binding protein, insulin-like growth factor-I (IGF-I), and IGF-I receptors in obesity and anorexia nervosa. Metabolism. 41:1992;106-112
26. Grinspoon S., Corcoran C., Stanley T., et al. Effects of androgen administration on the growth hormone-insulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab. 83:1998;4251-4256
27. Mulligan K., Grunfeld C., Hellerstein M.K., et al. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab. 77:1993;956-962
28. Helle S.I., Ueland T., Ekse D., et al. The insulin-like growth factor system in human immunodeficiency virus infection Relations to immunological parameters, disease progression, and antiretroviral therapy. J Clin Endocrinol Metab. 86:2001;227-233
29. Nam S.Y., Lee E.J., Kim K.R., et al. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord. 21:1997;355-359
30. Norrelund H., Frystyk J., Jorgensen J.O., et al. The effect of growth hormone on the insulin-like growth factor system during fasting. J Clin Endocrinol Metab. 88:2003;3292-3298
31. Katz L.E., DeLeon D.D., Zhao H., et al. Free and total insulin-like growth factor (IGF)-I levels decline during fasting Relationships with insulin and IGF-binding protein-1. J Clin Endocrinol Metab. 87:2002;2978-2983
32. Guler H.P., Zapf J., Froesch E.R. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med. 317:1987;137-140
33. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins Biological actions. Endocr Rev. 16:1995;3-34
34. Gomez J.M., Maravall F.J., Gomez N., et al. Interactions between serum leptin, the insulin-like growth factor-I system, and sex, age, anthropometric and body composition variables in a healthy population randomly selected. Clin Endocrinol (Oxf). 58:2003;213-219
35. Bereket A., Lang C.H., Blethen S.L., et al. Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus A possible role for insulin in the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab. 80:1995;2282-2288
36. Cotterill A.M., Holly J.M., Taylor A.M., et al. The insulin-like growth factor (IGF)-binding proteins and IGF bioactivity in Laron-type dwarfism. J Clin Endocrinol Metab. 74:1992;56-63
37. Timmins A.C., Cotterill A.M., Hughes S.C., et al. Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease. Crit Care Med. 24:1996;1460-1466
38. Giudice L.C., Farrell E.M., Pham H., et al. Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium Effects of a pregnancy-associated serum protease activity. J Clin Endocrinol Metab. 71:1990;806-816
39. Bunn R.C., Fowlkes J.L. Insulin-like growth factor binding protein proteolysis. Trends Endocrinol Metab. 14:2003;176-181
40. Heijligenberg R., Sauerwein H.P., Brabant G., et al. Circadian growth hormone secretion in asymptomatic human immune deficiency virus infection and acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 81:1996;4028-4032
41. Ho P.J., Gesundheit N., Wong W.L., et al. Dynamic changes of growth hormone-binding protein concentrations in normal men and patients with acromegaly Effects of short-term fasting. Metabolism. 44:1995;667-672
42. Baumann G., Amburn K., Shaw M.A. The circulating growth hormone (GH)-binding protein complex A major constituent of plasma GH in man. Endocrinology. 122:1988;976-984
43. Barnard R., Waters M.J. The serum growth hormone binding protein Pregnant with possibilities. J Endocrinol. 153:1997;1-14
44. Fisker S., Vahl N., Jorgensen J.O., et al. Abdominal fat determines growth hormone-binding protein levels in healthy nonobese adults. J Clin Endocrinol Metab. 82:1997;123-128
45. Schambelan M., Mulligan K., Grunfeld C., et al. Serostim Study Group. Recombinant human growth hormone in patients with HIV-associated wasting A randomized, placebo-controlled trial. Ann Intern Med. 125:1996;873-882
46. Engelson E.S., Glesby M.J., Mendez D., et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 30:2002;379-391
47. Kotler D.P., Muurahainen N., Grunfeld C., et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 35:2004;239-252
48. Lo J.C., Mulligan K., Noor M.A., et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab. 86:2001;3480-3487
49. Ghigo E., Aimaretti G., Maccario M., et al. Dose-response study of GH effects on circulating IGF-I and IGFBP-3 levels in healthy young men and women. Am J Physiol. 276:1999;E1009-E1013